Get the Stockscreener App
2.37
1.66%
-0.04
After Hours:
2.47
0.10
+4.22%
Spero Therapeutics Inc stock is traded at $2.37, with a volume of 479.43K.
It is down -1.66% in the last 24 hours and up +7.24% over the past month.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
See More
Previous Close:
$2.41
Open:
$2.39
24h Volume:
479.43K
Relative Volume:
1.62
Market Cap:
$133.52M
Revenue:
$29.32M
Net Income/Loss:
$-43.84M
P/E Ratio:
-2.9815
EPS:
-0.7949
Net Cash Flow:
$-27.67M
1W Performance:
-4.05%
1M Performance:
+7.24%
6M Performance:
+25.40%
1Y Performance:
+166.29%
1-Day Range:
$2.34
$2.48
1-Week Range:
$2.2901
$2.48
52-Week Range:
$0.5052
$3.22
Spero Therapeutics Inc Stock (SPRO) Company Profile
Name
Spero Therapeutics Inc
Sector
Industry
Phone
857-242-1600
Address
675 MASSACHUSETTS AVENUE, CAMBRIDGE, MA
Compare SPRO vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SPRO
Spero Therapeutics Inc
|
2.37 | 135.78M | 29.32M | -43.84M | -27.67M | -0.7949 |
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.73 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
692.83 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.60 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Spero Therapeutics Inc Stock (SPRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-23-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-01-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-22-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-16-20 | Initiated | Berenberg | Buy |
| Sep-29-20 | Initiated | Evercore ISI | Outperform |
| Nov-05-19 | Reiterated | H.C. Wainwright | Buy |
| Sep-09-19 | Initiated | Janney | Buy |
| Feb-09-18 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-27-17 | Initiated | BofA/Merrill | Neutral |
| Nov-27-17 | Initiated | Oppenheimer | Outperform |
| Nov-27-17 | Initiated | Stifel | Buy |
View All
Spero Therapeutics Inc Stock (SPRO) Latest News
Spero Therapeutics earnings beat by $0.73, revenue topped estimates - Investing.com
Spero Therapeutics shares jump over 4% on better-than-expected Q4 print - Investing.com Canada
Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update - The Manila Times
Spero Therapeutics Q4 revenue nearly triples, swings to profit - TradingView
Spero Therapeutics 2025 10-K: $66.8M Revenue, $0.15 EPS - TradingView
Spero Therapeutics (NASDAQ: SPRO) turns 2025 profit as tebipenem advances - Stock Titan
[10-K] Spero Therapeutics, Inc. Fi... - Stock Titan
Spero’s oral UTI antibiotic faces FDA decision on June 18 - Stock Titan
Can Spero Therapeutics Inc sustain earnings growth2026 Macro Impact & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Down 17.7% in 4 Weeks, Here's Why Spero Therapeutics (SPRO) Looks Ripe for a Turnaround - MSN
Analyst Calls: Is Spero Therapeutics Inc stock showing strong momentumWeekly Gains Summary & Fast Moving Stock Watchlists - baoquankhu1.vn
Spero Therapeutics (NASDAQ:SPRO) Downgraded by Wall Street Zen to "Hold" - MarketBeat
SPRO Stock Price, Quote & Chart | SPERO THERAPEUTICS INC (NASDAQ:SPRO) - ChartMill
Activity Recap: Is Spero Therapeutics Inc stock showing strong momentumPortfolio Gains Summary & Fast Gain Stock Tips - baoquankhu1.vn
Spero Therapeutics (SPRO) Expected to Announce Earnings on Thursday - MarketBeat
Spero Therapeutics Inc 預計每股虧損 55 美分財報前瞻 - TradingView
Spero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026 - marketscreener.com
Spero Therapeutics to post Q4 and 2025 results on March 26 - Stock Titan
Spero Therapeutics to Report Fourth Quarter and Full Year - GlobeNewswire
Weekly Earnings: What are Spero Therapeutics Incs recent SEC filings showingQuarterly Trade Report & Capital Efficient Trading Techniques - baoquankhu1.vn
Spero Therapeutics, Inc. (NASDAQ:SPRO) Sees Large Decline in Short Interest - MarketBeat
Profit Recap: Is Spero Therapeutics Inc stock showing strong momentumStop Loss & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Spero Therapeutics Inc erwartet einen Verlust von 55 Cents pro AktieEarnings Preview - TradingView
Spero Therapeutics (NASDAQ:SPRO) Stock Price Passes Above 50-Day Moving AverageHere's What Happened - MarketBeat
Dow Update: Can Spero Therapeutics Inc lead its sector in growth2025 Earnings Impact & Free High Return Stock Watch Alerts - baoquankhu1.vn
Stock Recap: Can Spero Therapeutics Inc ride the EV waveMarket Movers & Daily Chart Pattern Signals - baoquankhu1.vn
Big Picture: Will Spero Therapeutics Inc benefit from seasonalityWeekly Profit Summary & Weekly Market Pulse Alerts - baoquankhu1.vn
SPRO SEC FilingsSpero Therapeuti 10-K, 10-Q, 8-K Forms - Stock Titan
Short Interest in Spero Therapeutics, Inc. (NASDAQ:SPRO) Declines By 24.0% - MarketBeat
SPRO Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Spero Therapeutics (NASDAQ:SPRO) Shares Pass Above 200-Day Moving AverageShould You Sell? - MarketBeat
Can Spero Therapeutics Inc. (2HA) stock sustain margin levels2025 Trading Recap & Fast Entry Momentum Trade Alerts - mfd.ru
Aug PostEarnings: Can Spero Therapeutics Inc sustain earnings growth2025 Retail Activity & Low Drawdown Trading Strategies - baoquankhu1.vn
Valuation Update: Is Spero Therapeutics Inc stock showing strong momentum2025 Market Overview & Daily Volume Surge Signals - baoquankhu1.vn
Trade Alert: CEO, CFO Of Spero Therapeutics Esther Rajavelu Has Sold Stock - simplywall.st
Is Spero Therapeutics Inc. a good stock for dollar cost averaging2025 Price Targets & Weekly High Potential Stock Alerts - mfd.ru
Spero Therapeutics: Tebipenem’s FDA Path Supports A Speculative Buy (NASDAQ:SPRO) - Seeking Alpha
Esther Rajavelu Sells 87,917 Shares of Spero Therapeutics (NASDAQ:SPRO) Stock - MarketBeat
Keutzer, Spero Therapeutics COO, sells $44k in shares - Investing.com
Spero Therapeutics CEO sells $207k in stock By Investing.com - Investing.com Canada
Keutzer, Spero Therapeutics COO, sells $44k in shares By Investing.com - Investing.com Canada
Spero Therapeutics CEO sells $207k in stock - Investing.com
Aug Breakouts: What drives Spero Therapeutics Incs stock priceEarnings Summary Report & Safe Entry Zone Tips - baoquankhu1.vn
Spero Therapeutics (NASDAQ:SPRO) Insider Sells 18,442 Shares - MarketBeat
Spero Therapeutics (NASDAQ:SPRO) Stock Price Crosses Below 200 Day Moving AverageWhat's Next? - MarketBeat
Spero therapeutics exec Rajavelu sells $40k in shares By Investing.com - Investing.com Australia
Spero therapeutics exec Rajavelu sells $40k in shares - Investing.com
Spero Therapeutics announces board resignation and SEC investigation closure By Investing.com - Investing.com South Africa
Spero Therapeutics Co-Founder Resigns From Board Roles - TipRanks
SEC ends Spero Therapeutics (NASDAQ: SPRO) probe as director steps down - Stock Titan
SEC Enforcement Action Against Former Spero Executives: Individual Liability For Misleading FDA-Related Disclosures - marketscreener.com
Spero Therapeutics Inc Stock (SPRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.04%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):